Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults-Reference-Cited by-同舟云学术

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults

Published:2024-03-21 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Kulkarni Prasad S.¹,Padmapriyadarsini Chandrasekaran²,Vekemans Johan³,Bavdekar Ashish⁴,Gupta Madhu⁵,Kulkarni Praveen⁶,Garg B.S.⁷,Gogtay Nithya J.⁸,Tambe Muralidhar⁹,Lalwani Sanjay¹⁰,Singh Kiranjit¹¹,Munshi Renuka¹²,Meshram Sushant¹³,Selvavinayagam T.S.¹⁴,Pandey Krishna¹⁵,Bhimarasetty Devi Madhavi¹⁶,Ramakrishnan S.R.¹⁷,Bhamare Chetanraj¹,Dharmadhikari Abhijeet¹,Budhawant Chandrashekhar¹⁸,Bonhomme Cyrille J.¹⁹,Thakar Madhuri²,Kurle Swarali N.²,Kelly Elizabeth J.²⁰,Gautam Manish¹,Gupta Nivedita²,Panda Samiran²,Bhargava Balram²,Poonawalla Cyrus S.¹,Shaligram Umesh¹,Kapse Dhananjay¹,Gunale Bhagwat¹, ,Kawade Anand,Gondhali Arunkumar,Singh Mini P.,Mohindra Ritin,Pereiera Pratibha,Narayana Murthy M R,Raut Abhishek V.,Maliye Chetna,Kalantri Ashwini,Chaudhari Vijaya L L,Godbole Charuta J,Parande Malangori,Salunke Nandakumar,Palkar Sonali,Hanumante Neeta,Chaudhari Piyush,Karande Shilpa,Kumbhar Dipti,Gupta Shilpa,Mitra Sajal,Sudharshini S,Venkatesan Prakash,- Madhukar,Sen Abhik,Sreegiri Sunita,Vithanala Venkata Durga Prasad,Panneerselvam Tamilanbu,Nair Aiswarya M,Chaudhari Atul,Patil Silvester

Affiliation:

1. Serum Institute of India Pvt Ltd, Pune, India

2. Indian Council of Medical Research, Delhi, India

3. Formerly of: Clinical Development, Infection, Late-stage Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

4. KEM Hospital Research Centre, Pune, India

5. Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education & Research, Chandigarh, India

6. Department of Community Medicine, JSS Academy of Higher Education and Research, Mysore, India

7. Department of Community Medicine and Dr Sushila Nayar School of Public Health, Mahatma Gandhi Institute of Medical Sciences, Wardha, India

8. Department of Clinical Pharmacology, Seth G S Medical College & KEM Hospital, Mumbai, India

9. Department of Community Medicine, B J Government Medical College and Sassoon General Hospitals, Pune, India

10. Department of Pediatrics, Bharati Vidyapeeth Deemed University Medical College and Hospital, Pune, India

11. Jehangir Clinical Development Centre Pvt Ltd, Pune, India

12. Department of Clinical Pharmacology, TN Medical College & BYL Nair Hospital, Mumbai, India

13. Department of Pulmonary Medicine, Government Medical College, Nagpur, India

14. Directorate of Public Health and Preventive Medicine, Chennai, India

15. Rajendra Memorial Research Institute of Medical Sciences, Patna, India

16. Department of Community Medicine, Andhra Medical College, Visakhapatnam, India

17. Department of Clinical Research, Sri Ramchandra Institute of Higher Education and Research, Chennai, India

18. Biostatistics, PPD India Pvt Ltd, Mumbai, India

19. Laboratory Services, Vaccines Sciences Lab, Clinical Research, PPD, Part of Thermo Fisher Scientific, Richmond, VA, USA

20. Formerly of: Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

Funder

Indian Council of Medical Research

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2304974

Reference22 articles.

1. Ministry of Health and Family Welfare. Government of India. Coronavirus Dashboard. National Informatics Centre. 2023 [accessed 2023 Feb 1]. https://www.mohfw.gov.in/.

2. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India

3. World Health Organization. WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out. WHO; 2021 [accessed 2023 Feb 1]. https://www.who.int/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out.

4. Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

5. Antibody titres decline 3-month post-vaccination with BNT162b2